Skip to content
Screener

Upstream Bio, Inc. UPB Shares (Diluted)

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
142.7M+16.4%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
129.8M+154%
Savara logo
SavaraSVRA
253.6M+17.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$404.88M-54.7%
Enterprise value$326.44M-61.6%
P/S128.2×-200×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income, net2,6664,3815,6909,124
Net loss$(39,702)$(39,966)$(80,293)$(67,236)
Net loss per share attributable to common stockholders, basic and diluted$(0.73)$(0.74)$(1.47)$(1.25)
Weighted-average common shares outstanding, basic and diluted54,567,97653,770,86854,450,79853,694,424
Comprehensive loss:
Net loss$(39,702)$(39,966)$(80,293)$(67,236)
Unrealized gain (loss) on investments, net of tax(223)(110)(653)283
Total other comprehensive income (loss)(223)(110)(653)283

Item 1. Financial Statements.

FAQ

What is Upstream Bio, Inc.'s shares (diluted)?
Upstream Bio, Inc. (UPB) reported shares (diluted) of 54.6M in Q2 2026.
How has Upstream Bio, Inc.'s shares (diluted) changed year-over-year?
Upstream Bio, Inc.'s shares (diluted) increased by 1.5% year-over-year, from 53.8M to 54.6M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Upstream Bio, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude